News
PROK
1.830
+7.65%
0.130
Weekly Report: what happened at PROK last week (0615-0619)?
Weekly Report · 5d ago
Weekly Report: what happened at PROK last week (0608-0612)?
Weekly Report · 06/15 10:37
Weekly Report: what happened at PROK last week (0601-0605)?
Weekly Report · 06/08 10:32
ProKidney appoints Kenneth Locke as chief technical officer
TipRanks · 06/02 13:29
ProKidney names Kenneth Locke chief technical officer
PUBT · 06/02 12:06
PROKIDNEY APPOINTS KENNETH LOCKE AS CHIEF TECHNICAL OFFICER
Reuters · 06/02 12:00
Press Release: ProKidney Appoints Kenneth Locke as Chief Technical Officer
Dow Jones · 06/02 12:00
Weekly Report: what happened at PROK last week (0525-0529)?
Weekly Report · 06/01 10:38
ProKidney shareholders reaffirm board and auditor at 2026 meeting
TipRanks · 05/29 21:12
Weekly Report: what happened at PROK last week (0518-0522)?
Weekly Report · 05/25 10:42
ProKidney Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones · 05/18 15:09
HC Wainwright & Co. Reiterates Buy on ProKidney, Maintains $12 Price Target
Benzinga · 05/18 14:59
Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN) and ProKidney (PROK)
TipRanks · 05/18 14:40
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market
TipRanks · 05/18 12:45
Weekly Report: what happened at PROK last week (0511-0515)?
Weekly Report · 05/18 10:41
ProKidney GAAP EPS of -$0.14 beats by $0.01, revenue of $0.23M beats by $0.03M
Seeking Alpha · 05/18 06:03
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), ProKidney (PROK) and CG Oncology, Inc. (CGON)
TipRanks · 05/17 21:10
ProKidney's Loss Narrative Continues, But the Timing of Profitability Remains Anyone's Guess
Barchart · 05/17 16:00
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial
TipRanks · 05/15 16:20
More
Webull provides a variety of real-time PROK stock news. You can receive the latest news about ProKidney through multiple platforms. This information may help you make smarter investment decisions.
About PROK
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.